300 related articles for article (PubMed ID: 35313850)
1. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways.
Li Y; Xiong H
BMC Cancer; 2022 Mar; 22(1):298. PubMed ID: 35313850
[TBL] [Abstract][Full Text] [Related]
2. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway.
Xing Y; Liu Y; Qi Z; Liu Z; Wang X; Zhang H
Cell Mol Biol Lett; 2021 Nov; 26(1):49. PubMed ID: 34837962
[TBL] [Abstract][Full Text] [Related]
3. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
4. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
5. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
7. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
Ma XL; Shen MN; Hu B; Wang BL; Yang WJ; Lv LH; Wang H; Zhou Y; Jin AL; Sun YF; Zhang CY; Qiu SJ; Pan BS; Zhou J; Fan J; Yang XR; Guo W
J Hematol Oncol; 2019 Apr; 12(1):37. PubMed ID: 30971294
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
9. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
10. Piezoeletric cold atmospheric plasma induces apoptosis and autophagy in human hepatocellular carcinoma cells through blocking glycolysis and AKT/mTOR/HIF-1α pathway.
Wang Y; Mang X; Li D; Chen Y; Cai Z; Tan F
Free Radic Biol Med; 2023 Nov; 208():134-152. PubMed ID: 37543168
[TBL] [Abstract][Full Text] [Related]
11. SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway.
Wang H; Chen M; Yang C; Hu H; Jiang Y; Yang F; Lv L
Arch Biochem Biophys; 2023 Jul; 743():109661. PubMed ID: 37268273
[TBL] [Abstract][Full Text] [Related]
12. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
13. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
14. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
15. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
[TBL] [Abstract][Full Text] [Related]
16. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
17. LAGE3 promotes cell metastasis and stemness in non-small cell lung cancer companied with AKT/PI3K signaling pathway activation.
Zhang H; Jian J; Chen H; Zhu X; Xie J; Xu X
Pathol Res Pract; 2023 Aug; 248():154700. PubMed ID: 37473499
[TBL] [Abstract][Full Text] [Related]
18. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma.
Zhou K; Luo X; Wang Y; Cao D; Sun G
Biomed Pharmacother; 2017 Sep; 93():1025-1032. PubMed ID: 28732393
[TBL] [Abstract][Full Text] [Related]
20. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]